LTR Pharma (ASX:LTP) said it completed a successful pre-investigational new drug meeting with the US Food and Drug Administration, providing a defined path to approval for its SPONTAN intranasal spray, according to a Wednesday Australian bourse filing.
The meeting resulted in an alignment on a streamlined clinical development path, including one pivotal safety and efficacy trial and a multi-dose pharmacokinetic study.
The FDA broadly endorsed LTR's non-clinical toxicology and chemistry, manufacturing and controls development plans. It plans to investigate the ability to use additional clinical trial data for the US with other regulatory submissions in key global markets.
It also plans to introduce its vardenafil-based nasal spray Roxus into the US market. Roxus is being developed together with an Australian pharmaceutical partner in Australia and testing is being conducted to establish stability and shelf-life.
Its shares fell 9% as of market close on Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。